Professional Documents
Culture Documents
DOI: 10.3779/j.issn.1009-3419.2017.07.08
·综述·
肺结节评估四大指南比较分析
刘春全 崔永
影响肺结节的随访策略的主要因素是肺结节的影像
作者单位:100050 北京,首都医科大学附属北京友谊医院胸外科(通
讯作者:崔永,E-mail: cywork1@sina.com) 学特点以及患者自身的危险因素,影像学因素包括肺结
中国肺癌杂志
www.lungca.org
中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7 ·491·
表 1 实性结节影像学随访策略的区别
Tab 1 The difference of the follow up strategy of solid nodules
2017 No routine No routine CT at 6-12 Consider Optional Optional CT at CT at 6-12 mo Consider CT,
Fleischner follow-up follow-up mo, if CT, PET, CT at 12 12 mo then CT at PET or tissue
Society stable, then or tissue mo 18-24 mo sampling at 3 mo
Guidelines repeat CT at sampling
18-24 mo at 3 mo
2016 Annual CT CT at 12 mo CT at 6-12 CT at 3-6, Patient CT at 6-12 mo, CT at 3, 6, and PET scan if
Clinical surveillance and then mo, if 9-12, and discussion if stable, then 12 mo then hypermetabolic,
practice annual CT stable, then 18-24 repeat CT at annual CT surgical biopsy,
consensus surveillance repeat CT mo, if the 18-24 mo surveillance if surgical biopsy
guidelines at 18-24 mo nodule and then is positive, then
for Asia and then sclear annual CT surgical resection
annual CT growth surveillance
surveillance then
surgical
biopsy
CT: computed tomography; NCCN: National Comprehensive Cancer Network; ACCP: American College of Chest Physicians; PET: positron
emission computed tomography.
中国肺癌杂志
www.lungca.org
·492· 中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7
ACCP指南处理方案与NCCN大致相同。Fleischner协会指 CT或活检。亚洲共识指南建议低危人群3个月到半年之
南建议半年到1年复查CT,之后再考虑1年半到2年之间 间、9个月到1年之间、1年半到2年之间复查3次CT,若
复查CT。亚洲共识指南建议低危人群半年到1年之间、1 肺结节较前增大,则建议外科活检;建议中危人群行
年半到2年之间复查2次CT,以后每年复查1次CT;中、 PET-CT扫描,高度怀疑者可行外科活检,中低度怀疑者
高危人群分别在第3个月、半年、1年复查3次CT,以后 建议定期监测;建议高危人群行外科手术活检,若活检
每年复查1次CT。 结果为阳性,建议手术切除。
1.1.4 ≥8 mm NCCN和ACCP指南均建议在第3个月、第9 1.2 对于磨玻璃和部分实性结节影像学随访策略的区别
个月、2年复查3次CT,可行动态增强CT、PET和(或) (表2)
活检 [11]
。Fleischner协会指南建议3个月后复查CT、PET- 1.2.1 <5 mm孤立性纯磨玻璃结节 NCCN、Fleischner协会
表 2 磨玻璃和部分实性结节影像学随访策略的区别
Tab 2 The difference of the follow-up strategies between the ground-glass nodules and part solid nodules
Item Ground-glass nodules (mm) Part- solid nodules (mm)
<5 ≥5 to <6 ≥6 <5 ≥5 to <6 ≥6 to <8 ≥8
2016 No follow- CT at 3 mo, CT at 3 mo, and CT at 3 mo, and Biopsy or Biopsy or Biopsy or
NCCN up needed and annual annual CT for annual CT for at surgical surgical surgical
Guidelines CT for at at least 3 years least 3 years resection resection resection
least 3 years
中国肺癌杂志
www.lungca.org
中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7 ·493·
和ACCP指南均建议不需要随诊[12,13],亚洲共识指南建议 心组成的非盈利联盟,成立于1995年1月31日,致力于
每年复查1次CT。 提高患者的生活质量、提高疾病治疗的效果。NCCN最
1.2.2 ≥5 mm孤立性纯磨玻璃结节 NCCN指南建议3个月、 初由13个原始成员机构组成,他们基本都是来自临床专
1年、2年、3年共复查4次CT。ACCP指南与NCCN指南大 业的学科带头人和专家,目的是为卫生服务体系提供有
致相同,但强调3个月内不需要复查CT。亚洲共识指南建议 价值的信息资源,现任董事会主席是巴恩斯医院癌症中
每年复查1次CT,亚洲共识指南与Fleischner协会指南的区 心和华盛顿大学医学院的Timothy J. Eberlein教授。2016年
别在于亚洲共识要求连续3年复查CT后,如果结节无明显 11月,NCCN发布了2017年第3版非小细胞肺癌指南。通
变化,仍需继续年度复查CT,而Fleischner协会则建议3个 过搜索PubMed数据库获得2015年7月1日-2016年7月1日
月-6个月复查CT,确定病灶是否还存在,如果病灶不变或 之间非小细胞肺癌的关键文献,搜索的范围被缩小到人
者实性成分维持在<6 mm,需每年复查CT,满5年。 类身上研究的英文文章。文章类型主要包括:各阶段临
1.2.3 孤立部分实性结节 NCCN指南建议结节稳定或实 床试验、准则、荟萃分析、随机对照试验、系统评价和
性成分<5 mm时,3个月、1年、2年、3年复查4次CT;结节稳 验证研究。指南主要参考全国肺癌筛查试验(National
定或实性成分≥5 mm时,活检或手术切除 [14]
。ACCP指南 Lung Cancer Screening Trial, NLST),该实验涉及53,000多
建议结节≤8 mm时,3个月、1年、2年复查3次CT,然后 名目前或既往重度吸烟者,评估了低剂量CT扫描和胸
进行1年-3年的年度随访。建议结节>8 mm时,3个月复查1 片对肺癌患者进行检测的的风险和益处,并指出使用低
次CT,如果结节持续存在,需考虑PET、非手术活检或手术 LDCT扫描相对于胸片可以降低肺癌死亡率的20%[17,18]。
切除。如果结节发现时即>15 mm,直接进行PET,非手术活 NCCN、ACCP、美国预防服务工作组(United States
检或手术切除 。Fleischner协会指南建议结节>6 mm时,3
[15] Preventive Services Task Force, USPSTF)、欧洲肿瘤医学学
个月-6个月复查CT,确定病灶是否还存在,如果病灶不变 会(European Society for Medical Oncology, ESMO)、美国
或者实性成分维持在<6 mm,需每年复查CT,满5年;结节 外科医生学会(American College of Surgeons, ACS)和其他
≤6 mm时,无需常规随访。亚洲共识指南建议结节≤8 mm 组织推荐使用LDCT对高风险人群进行肺癌筛查,并强
时,3个月、1年、2年复查3次CT,然后每年复查1次CT;建 调LDCT的筛查不能代替戒烟[19-22]。NCCN指南提出对肺
议结节>8 mm时,3个月复查1次CT,可行抗炎治疗、手术或 结节进行评估时,需要胸外科、放射科、呼吸科等多学
非手术方式活检,活检前可先行PET-CT检测。 科共同合作,给出最优的诊断以及后续的治疗措施。病
1.3 对于多发亚实性结节影像学随访策略的区别(表3) 人自身的主要危险因素是吸烟,其与大多数肺癌患者死
NCCN指南建议纯磨玻璃密度结节≤5 mm时,第2年、 亡相关 [23-27]。患者自身已知的危险因素包括年龄、既往
第4年复查2次CT;纯磨玻璃密度结节>5 mm且无主病灶 的癌症病史、肺癌家族史、接触石棉、氡、铀等[28-32]、其
时,3个月复查1次CT,如果结节稳定,然后进行1年-3 他肺部疾病(慢性阻塞性肺病、肺纤维化) [33,34]、传染
年的年度随访;主要结节为部分实性或实性时,3个月复 性病原体接触(如真菌感染、结核病疫区)、表明感染
查1次CT,如果结节稳定,则推荐活检或手术切除 [16]
。 的高危因素病史(如免疫抑制、呼吸、传染性呼吸道症
Fleischner协会指南建议纯磨玻璃密度结节≤6 mm时,3 状)等。风险评估虽然可以用来衡量个人危险因素和影
个月-6个月复查CT,如果稳定,考虑第2年和第4年复查 像学的差异,但不会取代多学科评估对肺癌的诊断。
CT;纯磨玻璃密度结节>6 mm时,3个月-6个月复查CT, 2.2 Fleischner Society指南 Fleischner协会是一个国际多学
随后针对最有可疑的结节执行随访原则。ACCP指南目前 科胸部放射学医学会,主要研究胸部疾病的诊断和治
还没有针对多发性肺结节管理的明确指南。亚洲共识指 疗。协会于1969年由8名胸部影像学医生创建,主要成员
南建议对每个结节进行单独评估,不排除根治性治疗, 包括成人和儿科放射学专家,病理学家、胸外科医生、
酌情考虑病理学确认是否为转移。 生理学家、形态学家、流行病学及其他相关科学专家。
协会目前大约有70名成员,其中40名为高级成员,主席
2 四大指南背景、作者、筛查人群、循证医学证据的比 是William D. Travis教授。2005年Fleischner学会发表了肺实
较分析 性结节的处理指南,目前已经广泛用于临床[35]。然而,
越来越多的人意识到其非实性肺结节处理方案的不足。
2.1 NCCN指南 NCCN是一个由27个世界领先的癌症中 Fleischner学会总结了非实性肺结节的定义,并且查找
中国肺癌杂志
www.lungca.org
·494· 中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7
表 3 多发亚实性结节影像学随访策略的区别
Tab 3 The difference of the imaging follow-up strategy of multiple solid nodules
Item Multiple subsolid nodules (mm)
<5 ≥5 to <6 ≥6
2016 NCCN Guidelines CT at 2 and 4 years CT at 3 mo annual CT for at CT at 3 mo annual CT for at least 3
least 3 years years
2017 Fleischner Society Guidelines CT at 3-6 mo, if stable, CT at 3-6 mo, if stable, CT at 3-6 mo, subsequent
consider CT at 2 and 4 years consider CT at 2 and 4 years management based on the most
suspicious nodules
2013 ACCP Guidelines There are no clear guidelines multiple subsolid nodules
2016 Clinical practice Individual assessments of each nodule consider distant metastasis
consensus guidelines for Asia
中国肺癌杂志
www.lungca.org
中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7 ·495·
中国肺癌杂志
www.lungca.org
·496· 中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7
1 Ettinger DS. Ten years of progress in non-small cell lung cancer. J Natl 17 Research T, Aberle DR, Berg CD, et al. The National Lung Screening Trial:
Compr Canc Netw, 2012, 10(3): 292-295. overview and study design. Radiology, 2011, 258(1): 243-253.
2 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J 18 Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality
Clin, 2013, 63(1): 11-30. with low-dose computed tomographic screening. N Engl J Med, 2011,
Americans, 2013. CA Cancer J Clin, 2013, 63(3): 151-166. 19 Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer:
4 Brett GZ. The value of lung cancer detection by six-monthly chest Diagnosis and management of lung cancer, 3rd ed: American College of
radiographs. Thorax, 1968, 23(4): 414-420. Chest Physicians evidence-based clinical practice guidelines. Chest, 2013,
5 Frost JK, Ball WC Jr., Levin ML, et al. Early lung cancer detection: results 143(5 Suppl): e78S- e92S.
of the initial (prevalence) radiologic and cytologic screening in the Johns 20 Vansteenkiste J, Crino L, Dooms C, et al. 2nd ESMO Consensus Conference
Hopkins study. Am Rev Respir Dis, 1984, 130(4): 549-554. on Lung Cancer: early-stage non-small-cell lung cancer consensus on
6 Flehinger BJ, Melamed MR, Zaman MB, et al. Early lung cancer detection: diagnosis, treatment and follow-up. Ann Oncol, 2014, 25(8): 1462-1474.
results of the initial (prevalence) radiologic and cytologic screening in 21 Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United
the Memorial Sloan-Kettering study. Am Rev Respir Dis, 1984, 130(4): States, 2013: a review of current American Cancer Society guidelines,
555-560. current issues in cancer screening, and new guidance on cervical cancer
7 Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: screening and lung cancer screening. CA Cancer J Clin, 2013, 63(2):
results of the initial (prevalence) radiologic and cytologic screening in the 88-105.
Mayo Clinic study. Am Rev Respir Dis, 1984, 130(4): 561-565. 22 Moyer VA, Force USPST. Screening for lung cancer: U.S. Preventive
8 Kubik A, Parkin DM, Khlat M, et al. Lack of benefit from semi-annual Services Task Force recommendation statement. Ann Intern Med, 2014,
screening for cancer of the lung: follow-up report of a randomized 160(5): 330-338.
controlled trial on a population of high-risk males in Czechoslovakia. Int J 23 Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the
Cancer, 1990, 45(1): 26-33. effectiveness of radiotherapy with photons, protons and carbon-ions for
9 Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph non-small cell lung cancer: a meta-analysis. Radiother Oncol, 2010, 95(1):
and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian 32-40.
(PLCO) randomized trial. JAMA, 2011, 306(17): 1865-1873. 24 Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic
10 Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with lung radiotherapy for elderly patients with stage I non-small-cell lung
pulmonary nodules: when is it lung cancer? Diagnosis and management of cancer: a population-based time-trend analysis. J Clin Oncol, 2010, 28(35):
clinical practice guidelines. Chest, 2013, 143(5 Suppl): e93S-e120S. 25 Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5
11 Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of treatment strategies for early-stage non-small cell lung cancer in the elderly.
malignancy in solitary pulmonary nodules. Application to small Int J Radiat Oncol Biol Phys, 2012, 84(5): 1060-1070.
radiologically indeterminate nodules. Arch Intern Med, 1997, 157(8): 26 Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung
12 Maeshima AM, Tochigi N, Yoshida A, et al. Clinicopathologic analysis of Clin Oncol, 2010, 28(6): 928-935.
multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the 27 Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation
therapy versus surgical resection for stage I non-small cell lung cancer. J
中国肺癌杂志
www.lungca.org
中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7 ·497·
Thorac Cardiovasc Surg, 2010, 140(2): 377-386. Roentgenol, 2011, 196(3): 533-543.
28 Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III 43 Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of
non-small-cell lung cancer: seven-year follow-up of cancer and leukemia the current literature. Chest, 2003, 123(1 Suppl): 72S-82S.
group B (CALGB) 8433 trial. J Natl Cancer Inst, 1996, 88(17): 1210-1215. 44 Bach PB, Niewoehner DE, Black WC, et al. Screening for lung cancer: the
29 Baumann M, Herrmann T, Koch R, et al. Final results of the randomized guidelines. Chest, 2003, 123(1 Suppl): 83S-88S.
phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated- 45 Pinsky PF. An early- and late-stage convolution model for disease natural
accelerated versus conventionally fractionated radiotherapy in non-small history. Biometrics, 2004, 60(1): 191-198.
cell lung cancer (NSCLC). Radiother Oncol, 2011, 100(1): 76-85. 46 Hunt I, Siva M, Southon R, et al. Does lung cancer screening with chest
30 Mauguen A, Le Pechoux C, Saunders MI, et al. Hyperfractionated or X-ray improve disease-free survival? Interact Cardiovasc Thorac Surg,
accelerated radiotherapy in lung cancer: an individual patient data meta- 2006, 5(4): 483-487.
analysis. J Clin Oncol, 2012, 30(22): 2788-2797. 47 Manser RL, Irving LB, Byrnes G, et al. Screening for lung cancer: a
31 Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative systematic review and meta-analysis of controlled trials. Thorax, 2003,
chemoradiation in addition to preoperative chemotherapy: a randomised 58(9): 784-789.
trial in stage III non-small-cell lung cancer. Lancet Oncol, 2008, 9(7): 48 Manser RL, Irving LB, Stone C, et al. Screening for lung cancer. Cochrane
636-648. Database Syst Rev, 2004(1): CD001991.
32 Higgins K, Chino JP, Marks LB, et al. Preoperative chemotherapy versus 49 Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening
preoperative chemoradiotherapy for stage III (N2) non-small-cell lung for lung cancer: a systematic review. JAMA, 2012, 307(22): 2418-2429.
cancer. Int J Radiat Oncol Biol Phys, 2009, 75(5): 1462-1467. 50 Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A
33 Curran WJ, Jr., Paulus R, Langer CJ, et al. Sequential vs. concurrent critique of the Mayo Lung Project. Cancer, 1991, 67(4 Suppl): 1155-1164.
chemoradiation for stage III non-small cell lung cancer: randomized phase 51 Blanchon T, Brechot JM, Grenier PA, et al. Baseline results of the Depiscan
III trial RTOG 9410. J Natl Cancer Inst, 2011, 103(19): 1452-1460. study: a French randomized pilot trial of lung cancer screening comparing
34 Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer, 2007,
regionally advanced unresectable non-small cell lung cancer: Radiation 58(1): 50-58.
Therapy Oncology Group, Eastern Cooperative Oncology Group, and 52 Garg K, Keith RL, Byers T, et al. Randomized controlled trial with low-
Southwest Oncology Group. Chest, 2000, 117(2): 358-364. dose spiral CT for lung cancer screening: feasibility study and preliminary
35 Eisenberg RL, Bankier AA, Boiselle PM. Compliance with Fleischner results. Radiology, 2002, 225(2): 506-510.
Society guidelines for management of small lung nodules: a survey of 834 53 Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of the Lung
radiologists. Radiology, 2010, 255(1): 218-224. Screening Study, a randomized feasibility study of spiral CT versus chest
36 Travis WD, Brambilla E, Noguchi M, et al. International association X-ray screening for lung cancer. Lung Cancer, 2005, 47(1): 9-15.
for the study of lung cancer/american thoracic society/european 54 Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and
respiratory society international multidisciplinary classification of lung baseline results of the ITALUNG trial for lung cancer screening with low-
adenocarcinoma. J Thorac Oncol, 2011, 6(2): 244-285. dose CT. Lung Cancer, 2009, 64(1): 34-40.
37 Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of 55 Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer
peripheral adenocarcinomas of the lung: recommended interim guidelines screening with spiral computed tomography: three-year results from the
for assessment and management. Radiology, 2009, 253(3): 606-622. DANTE trial. Am J Respir Crit Care Med, 2009, 180(5): 445-453.
38 Kim HK, Choi YS, Kim J, et al. Management of multiple pure ground-glass 56 Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings
opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac forward early disease. The randomised Danish Lung Cancer Screening
Oncol, 2010, 5(2): 206-210. Trial: status after five annual screening rounds with low-dose CT. Thorax,
39 Kim HK, Choi YS, Kim K, et al. Management of ground-glass opacity 2012, 67(4): 296-301.
lesions detected in patients with otherwise operable non-small cell lung 57 Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al. Early lung cancer
cancer. J Thorac Oncol, 2009, 4(10): 1242-1246. detection using spiral computed tomography and positron emission
40 Jeudy J, White CS, Munden RF, et al. Management of small (3-5-mm) tomography. Am J Respir Crit Care Med, 2005, 171(12): 1378-1383.
pulmonary nodules at chest CT: global survey of thoracic radiologists. 58 Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action
Radiology, 2008, 247(3): 847-853. project: initial findings on repeat screenings. Cancer, 2001, 92(1): 153-159.
41 van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung 59 Menezes RJ, Roberts HC, Paul NS, et al. Lung cancer screening using low-
nodules detected by volume CT scanning. N Engl J Med, 2009, 361(23): dose computed tomography in at-risk individuals: the Toronto experience.
2221-2229. Lung Cancer, 2010, 67(2): 177-183.
42 Goo JM, Park CM, Lee HJ. Ground-glass nodules on chest CT as imaging 60 Kim YK, Lee SH, Seo JH, et al. A comprehensive model of factors affecting
biomarkers in the management of lung adenocarcinoma. AJR Am J adoption of clinical practice guidelines in Korea. J Korean Med Sci, 2010,
中国肺癌杂志
www.lungca.org
·498· 中国肺癌杂志2017年7月第20卷第7期 Chin J Lung Cancer, July 2017, Vol.20, No.7
Cite this article as: Liu CQ, Cui Y. Lung nodules assessment--analysis of four guidelines. Zhongguo Fei Ai Za Zhi, 2017, 20(7):
490-498. [刘春全, 崔永. 肺结节评估四大指南比较分析. 中国肺癌杂志, 2017, 20(7): 490-498.] doi: 10.3779/j.issn.1009-3419.20
17.07.08
·消息·
《中国肺癌杂志》被CSCD(2017-2018年度)收录
2017年3月,由中国科协主管、中国抗癌协会、中国防痨协会和天津医大总医院主办的《中国肺癌杂
志》继续被中国科学引文数据库(CSCD)2017-2018年度收录为核心期刊(以C标记),至此,《中国肺癌
杂志》已经被美国Medline,荷兰SCOPUS,中国统计源目录,北大核心与中科院CSCD数据库全部收录为核
心期刊!
中国科学引文数据库(Chinese Science Citation Database, CSCD)创建于1989年,收录我国数学、物理、
化学、天文学、地学、生物学、农林科学、医药卫生、工程技术和环境科学等领域出版的中英文科技核心期
刊和优秀期刊千余种,目前已积累从1989年到现在的论文记录4,690,808条,引文记录57,967,579条。中国科学
引文数据库内容丰富、结构科学、数据准确。系统除具备一般的检索功能外,还提供新型的索引关系——引
文索引,使用该功能,用户可迅速从数百万条引文中查询到某篇科技文献被引用的详细情况,还可以从一篇
早期的重要文献或著者姓名入手,检索到一批近期发表的相关文献,对交叉学科和新学科的发展研究具有十
分重要的参考价值。中国科学引文数据库还提供了数据链接机制,支持用户获取全文。
中国科学引文数据库具有建库历史最为悠久、专业性强、数据准确规范、检索方式多样、完整、方便
等特点,自提供使用以来,深受用户好评,被誉为“中国的SCI”。
2017年-2018年度中国科学引文数据库收录来源期刊1,229种,其中中国出版的英文期刊201种,中文期刊
1,028种。中国科学引文数据库来源期刊分为核心库和扩展库两部分,其中核心库885种;扩展库344种。
中国科学引文数据库来源期刊每两年遴选一次。每次遴选均采用定量与定性相结合的方法,定量数据
来自于中国科学引文数据库,定性评价则通过聘请国内专家定性评估对期刊进行评审。定量与定性综合评估
结果构成了中国科学引文数据库来源期刊。
中国肺癌杂志
www.lungca.org